CD34 and plasma cell myeloma: performed a purging using CD34+ selection to remove contaminated myeloma cells from autografts, thereby reducing the number of myeloma cells, although could not demonstrate improved disease‐free survival and OS possibly owing to the relatively large number of myeloma cells in patients pre‐ASCT despite receiving contamination‐free autografts.